March 29th 2023
Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).
January 25th 2023
Tanios Bekaii-Saab, MD, on the Past Year in Gastrointestinal Cancer ResearchDecember 29th 2020
The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.
Study Suggests Need to Develop Therapeutic Modalities to Target Early-Onset Appendiceal CancerDecember 26th 2020
This study indicated that appendiceal cancer diagnosed among younger individuals harbors a distinct genomic landscape, as compared with appendiceal cancer diagnosed among older individuals.
FDA Grants Priority Review to Pembrolizumab Plus Chemo for Advanced Esophageal or GEJ CancerDecember 17th 2020
The FDA granted priority review to a new supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
UDCA May Be Associated with Reduction of Biliary Tract Cancer, Need for Liver TransplantationNovember 24th 2020
Data from a Japanese cohort of patients with primary sclerosing cholangitis suggested ursodeoxycholic acid (UDCA) was significantly associated with reduced mortality or need for liver transplantation and was also likely to be associated with a reduction of biliary tract cancer.
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Gastric, GEJ CancerOctober 28th 2020
The FDA granted priority review to the supplemental biologics license application for trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
John L. Marshall, MD, on Accessibility of Precision MedicineOctober 2nd 2020
The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.
Phase 3 ORIENT-32 Trial Shows Promise for First-Line Treatment Combo in HCCSeptember 28th 2020
The study is evaluating the efficacy and safety of sintilimab injection in combination with bevacizumab biosimilar injection compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma.
Compared to Standard of Care, HAIC Demonstrates Better Safety and Efficacy in Unresectable HCCSeptember 24th 2020
Hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin significantly improved overall survival compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Adding Nivolumab to Chemo Improves PFS, Elicits Higher ORR in Gastric/GEJ CancersSeptember 24th 2020
The addition of nivolumab (Opdivo) to chemotherapy resulted in a statistically significant improvement in PFS and evoked higher ORRs in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.
Phase 3 CheckMate-649 Study Sees Promising Survival Benefit with Frontline Nivolumab, Chemo ComboSeptember 22nd 2020
The combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Phase 3 KEYNOTE-590 Trial Finds Pembrolizumab, Chemo Combo Effective for Advanced Esophageal CancerSeptember 21st 2020
Frontline pembrolizumab (Keytruda) plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.
Phase 2 Study Shows Promise for Dabrafenib, Trametinib Combo in BRAFV600E-Mutated Biliary Tract CancerAugust 20th 2020
Researchers indicated that results of this study suggest the combination of dabrafenib and trametinib could serve as a much-needed treatment option for patients with BRAFV600E-mutated biliary tract cancer.
Phase 3 KEYNOTE-590 Trial of Pembrolizumab Plus Chemo Meets Primary End Points of OS, PFSAugust 19th 2020
The trial is evaluating pembrolizumab (Keytruda) in combination with cisplatin plus 5-fluorouracil for the first-line treatment of patients with locally advanced or metastatic esophageal cancer.
Trial Evaluating Nivolumab for Patients with Esophageal Cancer Meets Primary End Point of DFSAugust 11th 2020
Bristol Myers Squibb’s CheckMate-577 trial, which evaluated nivolumab to treat patients with resected esophageal or gastroesophageal junction cancer, met the primary end point of disease-free survival.
Effect of Lifestyle Factors and Garlic Supplementation on Gastric Cancer IncidenceJuly 20th 2020
This study found that smoking was associated with an increased risk of gastric cancer incidence and mortality, while not drinking was correlated with a stronger beneficial effect of garlic supplementation on gastric cancer prevention.
Xin Wei Wang, PhD, on New Blood Test Able to Identify Those Likely to Develop HCCJuly 14th 2020
The co-leader of the NCI Center for Cancer Research Liver Cancer Program discussed the clinical utility of the blood test and how it could potentially change liver cancer diagnoses moving forward.
FDA Issues Complete Response Letter for Pembrolizumab plus Lenvatinib in Unresectable HCCJuly 8th 2020
Merck and Eisai announced that the FDA issued a complete response letter to its accelerated approval applications for the combination use of pembrolizumab plus lenvatinib to treat patients with unresectable hepatocellular carcinoma.
Trastuzumab Deruxtecan Leads to Improved Response and OS in HER2+ Gastric CancerJuly 2nd 2020
In this open-label, randomized, phase 2 trial, treatment with trastuzumab deruxtecan led to significant improvements in response and overall survival in patients with HER2-positive gastric cancer.
FDA Approves Nivolumab to Treat Advanced Esophageal Squamous Cell CarcinomaJune 11th 2020
The FDA approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.